This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Erbitux Has Expanded Potential

Furthermore, patients in the Erbitux arm had two- and three-year survival rates of 62% and 57%, respectively, compared to respective two- and three-year survival rates of 55% and 44% for patients in the radiation-only arm.

"The use of cetuximab Erbitux and radiation therapy may become an excellent choice of therapy for this group of patients," Dr. James Bonner, a radiation oncologist at the University of Alabama and the lead investigator of the study, said in a statement. "Future studies should be performed to examine combinations of chemotherapy, radiation therapy and cetuximab Erbitux ."

Saturday's data presentation was conducted by ASCO for journalists as part of a media briefing highlighting medical advances in lung and head and neck cancer. A full airing of this Erbitux data in front of the attendees at ASCO's annual meeting is scheduled for Tuesday.

One hitch in this Erbitux study is that it was started in 1999, and since then, doctors have altered the way they treat patients with so-called front-line, advanced head and neck cancer. Instead of using radiation alone, the standard of care is now the combination of radiation and chemotherapy. Since the study did not include the use of chemotherapy, ImClone may find it difficult to use the study as the basis for a new FDA approval filing.

Still, given the survival benefit driven by Erbitux, doctors are likely to use the drug "off label," especially in head and neck cancer patients who can't tolerate chemotherapy. Some doctors may also assume that if radiation and chemotherapy work, then a triple combination of radiation, chemotherapy and Erbitux will work even better. There has been data presented at past ASCO meetings that showed evidence of Erbitux and chemotherapy working synergistically in head and neck cancer, just like it does in colon cancer.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,078.89 +48.68 0.27%
S&P 500 2,090.30 +8.42 0.40%
NASDAQ 4,800.3320 +26.86 0.56%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs